



APASL Oncology 2026 TOKYO

Luncheon Seminar 2

Future Multidisciplinary Treatment Strategies Based on Therapeutic Goals and Tumor Status

Chair

Masafumi Ikeda MD, PhD

Deputy Director and Chief, Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Japan

池田 公史 先生 (国立がん研究センター東病院 副院長 / 肝胆膵内科 科長)

Speakers

1

Nobuhito Taniki MD, PhD

Assistant Professor, Keio University, School of Medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Japan

谷木 信仁 先生 (慶應義塾大学医学部 消化器内科 専任講師)

Deepening and Advancing Multidisciplinary Treatment for Hepatocellular Carcinoma: Tumor Status-Based Approaches Combining Lenvatinib and Interventional Radiology

Speakers

2

Teiji Kuzuya, MD, PhD

Professor, Department of Gastroenterology and Hepatology, Fujita Health University, Japan

葛谷 貞二 先生 (藤田医科大学医学部 消化器内科学 臨床教授)

Optimizing Drug Sequencing and Integrated Strategies in Hepatocellular Carcinoma: Maximizing the Therapeutic Potential of Lenvatinib in the ICI Era

2026

4/2

Thursday

Thursday, April 2, 2026

12:00~13:00

Seminar Room, 3F

▶ This seminar is for healthcare personnel only.

▶ Please refrain from reproducing, reprinting, modifying, or using for any other secondary purposes the contents of this seminar (including, without limitation, any statements and projected text, photographs, diagrams and illustrations) without permission.

Sponsored by APASL Oncology 2026 TOKYO / Eisai Co.,Ltd.